Table 1.
Study Characteristics
| Reference, Year | Official Acronym (Sample Size) | Active Drugs | Comparator | Treatment Duration, mo | Characteristics of Participants (Age, y) |
|---|---|---|---|---|---|
| Ogihara, 20147, 8, 9 | COLM (n=5023) | ARB+CCB | ARB+D | >36 | Hypertensives (65–84) with a history of cardiovascular disease |
| Matsuzaki, 201110, 11, 12 | COPE (n=2199) | ARB+CCB | BB+C | 9 | Outpatients (40–85) with hypertension and without obvious CV or metabolic disease |
| Boutouyrie, 201013 | EXPLOR (n=393) | ARB+CCB | BB+C | 1+2+4a | Hypertensives (18–75) resistant to two drugs belonging to two different pharmacologic classes |
| Matsui, 200914, 15, 16 | J‐CORE (n=207) | ARB+CCB | ARB+D | 3+6a | Hypertensives (30–85) |
| Jamerson, 20083, 17 | ACCOMPLISH (n=11506) | ACE inhibitor+CCB | ACE inhibitor+D | 30 | Hypertensives (>55) without obvious CV or metabolic disease |
| Bakris, 200818 | GUARD (n=332) | ACE inhibitor+CCB | ACE inhibitor+D | 12 | Hypertensives (21–85) with type 2 diabetes mellitus and albuminuria |
| Roca‐Cusachs, 200819 | – (n=314) | ACE inhibitor+CCB | ARB+D | 3 | Hypertensives (63.6±8.8) with noninsulin‐dependent type 2 diabetes |
| Holzgreve, 200320 | – (n=450) | ACE inhibitor+CCB | BB+D | 5 | Hypertensives (40–80) with noninsulin‐dependent type 2 diabetes |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BB, β‐blocker; CCB, calcium channel blocker; D, diuretic; CV, cardiovascular. aTreatment duration with two‐agent therapy. See text for trial expansions.